logo
Colorectal cancer signs, symptoms & screening: Everything you need to know about the 2nd deadliest cancer in Canada

Colorectal cancer signs, symptoms & screening: Everything you need to know about the 2nd deadliest cancer in Canada

Yahoo07-03-2025

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle.
Colorectal Cancer Awareness Month is back this March, and one non-profit is encouraging Canadians to learn more about the disease and how its screened. That includes understanding how colorectal cancer can be preventable, treatable and beatable if caught early.
For March, Colorectal Cancer Canada launched a new campaign this year called Make Your #2 Your #1 Priority. "Our objective is to make all Canadians aware that colorectal cancer can affect everyone, that it exists and 69 Canadians each day are diagnosed," the non-profit stated in its campaign, which focuses on changes in bowel movements.
President and CEO of Colorectal Cancer Canada Barry Stein urged people to take their health into their own hands because screenings can save your life. "No one should wait until symptoms appear because, by then, it may be too late," the stage four colorectal cancer survivor shared in a news release.
Stein previously shared five things Canadians should and shouldn't do when it comes to managing their health and preventing colorectal cancer. Those included everything from paying attention to symptoms and maintaining a healthy lifestyle.
View this post on Instagram
A post shared by Colorectal Cancer Canada (@coloncanada)
Colorectal Cancer Canada is also urging people to wear blue on Friday, March 7 in support of people impacted by the disease. Similar to last week's Pink Shirt Day to raise awareness around bullying, the organization's Dress in Blue Day aims for people to wear a blue-coloured clothing item — anything from a T-shirt to socks — to help spread awareness about colorectal cancer.
Canadian screening policies recommend average-risk adults get screened for colorectal cancer at age 50 and above. However, rates of the disease in younger people have been rapidly rising worldwide. Even celebrities like former Dawson's Creek star James Van Der Beek, who was diagnosed with stage three colorectal cancer last year when he was 47, have faced the disease head on.
In Canada, an estimated 25,200 people were diagnosed with colorectal cancer last year. The Canadian Cancer Society indicated that represents 10 per cent of all new cancer cases diagnosed last year, adding that around 9,400 people died from the disease in 2024. In the U.S., there may be more than 154,000 new colorectal cancer cases diagnosed in 2025.
One Canadian who experienced colorectal cancer at an early age is Ontario-based rapper Bishop Brigante. The Scarborough, Ont.-bred artist was first diagnosed with colorectal cancer in October 2023.
"I'm 45. I could've been fighting this in my 30s," Brigante previously told Yahoo Canada. "I could've been fighting this sooner and it would've been a completely different fight."
In late January 2024, Brigante created a petition urging medical professionals and policymakers to push for a lower age criteria when it comes to colonoscopies in Canada. At more than 37,000 signatures, the petition urges for that criteria to be set at age 30, specifically for men.
"I honestly believe if they take away this age criteria, we will save so many lives, and that's important to me."Bishop Brigante
But what exactly is colorectal cancer and should Canadians worry about developing the disease? Read on to learn more.
Colorectal cancer is a disease that affects your large intestine (colon) or your rectum (the end of the colon). Colon and rectal cancers are grouped together as colorectal cancer because the two organs are made of the same tissues without a distinct border between them.
When cells in the colon or rectum no longer grow or behave normally, the changes may lead to non-cancerous tumours, precancerous conditions (i.e. adenomas) or colorectal cancer.
Colorectal cancer may not present any significant signs or symptoms in its early stages, making it all the more important to stay up-to-date on your colon health and get screened regularly. If caught in its early stages, colorectal cancer is 90 per cent curable.
According to the American Cancer Society, a polyp can take as long as 10 to 15 years to develop into cancer. Therefore, symptoms often only start appearing once a tumour grows and affects the surrounding organs and tissues. The early signs of colorectal cancer are often similar to other health conditions, including anemia and irritable bowel syndrome.
Dr. Monika Krzyzanowska, a medical oncologist at the Princess Margaret Cancer Centre, told Yahoo Canada in a previous interview that one of the early signs of the disease is a change in bowel habits: "[People] may not be going as often [to the bathroom] as they usually do. The calibre of your stool may change. For example, it can become thinner or more narrow."
Krzyzanowska noted abdominal pain, bleeding and unexplained weight loss are causes for concern, alongside iron-deficiency anemia: "One of the things people may not know [to pay attention to] is iron-deficiency anemia. They may be feeling tired, go see their family doctor and are found to be anemic. This can sometimes be an initial presentation of colon cancer."
Other signs or symptoms of colorectal cancer may include:
Diarrhea
Constipation
Narrow stool (compared to average)
Blood in the stool
Unexplained weight loss
Anemia
Abdominal cramps and pain
Nausea and vomiting
Pain or discomfort in the rectum
Bleeding from the rectum
Krzyzanowska indicated the urgent symptoms you should never ignore are "any sort of severe abdominal pain or abdominal pain associated with nausea, vomiting and an inability to pass stool," as they could be symptoms of a bowel obstruction.
While colorectal cancer can affect anyone, people living with inflammatory bowel disease such as Crohn's disease or ulcerative colitis are at an increased risk compared to others. Risk factors include a family history of polyps and colon cancer, obesity, smoking, alcohol, sedentary behaviour and a diet high in processed food and red meat.
"Ironically, a lot of the lifestyle factors [that are good for colon health] are good for other things as well," Krzyzanowska said, adding that "having a healthy diet, not smoking and having a good weight" can decrease your risk of the disease.
View this post on Instagram
A post shared by Colorectal Cancer Canada (@coloncanada)
For 2025, the American Cancer Society projected the United States will see more than two million new cancer diagnoses, which equates to about 5,600 new cases per day. Moreover, there could be more than 618,000 cancer deaths this year, according to the organization's annual cancer statistics report. Despite this growth, no one can say for certain why colorectal cancer numbers are increasing amongst young people.
However, some experts theorize increased incidence rates could be linked to sedentary lifestyles, obesity, smoking, heavy alcohol use, environmental factors and poor diets. Still, learning your family history of colorectal cancer, getting regular medical checkups, exercising and consuming a good diet are all key to leading a healthy life.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dog Fighting Cancer 4 Months Ago Now Living His Best Life in Switzerland
Dog Fighting Cancer 4 Months Ago Now Living His Best Life in Switzerland

Newsweek

timean hour ago

  • Newsweek

Dog Fighting Cancer 4 Months Ago Now Living His Best Life in Switzerland

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A 7-year-old Samoyed named Boomer has captured hearts on social media after a remarkable recovery from cancer, which his owners celebrated with a family vacation to Europe. In an Instagram video shared on Sunday under the username @ the fluffy pup can be seen lounging on a swing chair in the Swiss mountains, cuddling his favorite toy while enjoying a nap in the sunshine. "Four months ago my dog was fighting cancer and now here he is... cuddling with his favorite toy in Switzerland. He even fell asleep like this!" the poster writes in the clip. "Never taking a day with him for granted," the caption says. The poster, Charishma Cohen, from Oregon, told Newsweek that Boomer's health issues began in September 2024, when he suddenly started throwing up huge amounts of blood every few weeks and vets couldn't figure out what was wrong. A screenshot of the viral clip shows the pup cuddling with his toy on his celebratory vacation. A screenshot of the viral clip shows the pup cuddling with his toy on his celebratory vacation. getty images "After multiple medications and diagnostics, during an ultrasound the internal specialist noticed a growth in his adrenal gland which was growing fast. In February he had a surgery to remove his left adrenal gland and they determined it was cancer," she said. Adrenal glands are vital for regulating stress responses, blood pressure, metabolism, and electrolyte balance, says Pet MD. Common types of adrenal tumors include adrenal adenomas (benign), adrenal carcinomas (malignant and prone to spreading) peochromocrytomas, and paragangliomas. These usually affect middle-aged to older dogs, with larger breeds more at risk. While causes remain unclear, genetics, environment, and diet may play a role. Symptoms and severity depend on the tumor type and the hormones involved. Boomer will need consistent testing to make sure it doesn't come back, although thankfully he is doing really well now. "To celebrate we took him on a 10-week trip to Europe and he's having the best vacation and it's so nice to see him healthy and happy again after so many months of him feeling so bad," she said. "This experience made us realize really how little time we get with our dogs so it's made us want to embrace every moment with him even more! Life is short!" The video has proved popular online, receiving over 66,300 views and 6,516 likes since being posted. One user, La_dolce_alaska, commented: "Love to see it! Enjoy life to the fullest!" Macarenarodriguezo said: "Oh my god!!! This gives me so much hope for my furry baby. We are just on our third chemo for lymphoma and it's been a horrible couple of months since we found out the news so seeing your baby so relax and living his best life, helps to tame some of the ache in my heart." Mello_thesamoyed added: "He deserves every second of this amazing trip." Do you have funny and adorable videos or pictures of your pet you want to share? Send them to life@ with some details about your best friend and they could appear in our Pet of the Week lineup.

Child-Free Woman Praised for Eye-Opening Question to Parents
Child-Free Woman Praised for Eye-Opening Question to Parents

Newsweek

time3 hours ago

  • Newsweek

Child-Free Woman Praised for Eye-Opening Question to Parents

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A child-free woman from Ontario, Canada, has been praised online after asking parents a thought-provoking question. Tiffany J. Marie (@ told Newsweek the reaction after she said that parents who visit her page tell her she will "never know what it's like" to have kids. "'I love them unconditionally, it's visceral. I would die for my child. OK, but would you live for them?" Marie asked in a reel on Instagram. From left: Tiffany J. Marie holds a cup of coffee while speaking to the camera. From left: Tiffany J. Marie holds a cup of coffee while speaking to the camera. @ "Would you go to therapy? Would you get healthy? Would you go to rehab? Would you stop drinking? Would you exercise? Would you better yourself as a human? Because dying for someone is easy. You just die … But living for your child; changing yourself; being introspective—that's love." Marie said that her post was inspired by the hypocrisy she experiences as a child-free woman. "There's a lot of pressure for women to have kids, a lot of people pushing the idea that you'll regret remaining without children, disregarding just how deeply we've considered the weight of responsibility that comes with parenting," Marie said. She continued: "Almost all child-free people have thought about the impact of bringing a child into the world, and it made me wonder just how many parents have done the same." Marie said living for a child means more than financial support or birthday parties. "[It's] actively trying to end those generational traumas; it's admitting you're wrong sometimes and being able to apologize, making healthy choices in all categories of life; it's making positive change," Marie said. "It's really something we should all be doing for ourselves, but if the love of a child is so much more intense than anything else, it seems that should be enough to motivate a parent to make those changes," she said. Marie's reel, which been viewed over 10 million times, garnered a mixed response. Some comments included a handful of applause emoji. "Outright dying is easier than dying to self. Love this perspective," one user wrote. "Parent here. Bookmarking this. Brilliant," another commented. However, not all parents agreed and questioned Tiffany's choice to be child-free. "For someone who purports to be so happily childless this woman spends a lot of time on the internet worrying about those who do have kids," one user wrote. Marriage and family therapist Becky Whetstone, Ph.D., told Newsweek that being a role model for mental, physical, and spiritual health is crucial for any parent. "Words mean little in the end, but showing your children how to live life as a confident, balanced human, who nurtures their individuality outside the family and deals with life's obstacles head-on as a powerful, capable, healthy human is the best example of good parenting," Whetstone said. Marie told Newsweek that her reel provoked a mixed reaction online. "There's been a wonderful outpouring from parents who've shared they are living for their kids and making positive changes, but just as many comments from children of parents who've failed to measure up," Marie said. "It shows that simply having children isn't going to fundamentally change someone who doesn't want to change, and love sometimes isn't enough."

Health Canada approves Novartis' KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence
Health Canada approves Novartis' KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Yahoo

time3 hours ago

  • Yahoo

Health Canada approves Novartis' KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Despite endocrine therapy (ET), the risk of recurrence for people diagnosed with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) early breast cancer (eBC) remains high, in addition to the possibility of an incurable metastatic relapse.1 Health Canada approval is based on the pivotal Phase III NATALEE trial data, which demonstrated a clinically meaningful invasive disease-free survival (iDFS) benefit for KISQALI® plus adjuvant aromatase inhibitor (AI) in patients with stage II or III HR+/HER2- eBC.2 KISQALI is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival in three Phase III trials in advanced breast cancer.3,4,5 MONTREAL, June 18, 2025 /CNW/ - Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib tablets) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of adult patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) stage II-III early breast cancer (eBC) at high risk of recurrence.2 Breast cancer is one of the most common cancers globally,6 with HR+/HER2- being the most prevalent subtype, accounting for approximately 70% of cases.7,8,9 Over 40% of HR+/HER2- breast cancer cases are diagnosed at stage II or III, with a high risk of recurrence for up to 20 years.8,9 If cancer recurs, it is often metastatic which in most cases is considered incurable.10,11 This progression significantly increases the burden on patients, caregivers, and healthcare systems, both financially and emotionally.11,12 On average, 15 Canadian women will die from breast cancer every day.13 "Over our years supporting younger patients, we've seen far too many with HR+ breast cancer become metastatic even while on maintenance endocrine therapy," said MJ DeCoteau, Founder and Executive Director, Rethink Breast Cancer. "Breast cancer is often more aggressive in younger patients, and they have higher rates of recurrence despite early treatment. So, we were thrilled to see that the positive results for KISQALI for early breast cancer are the same for patients of all ages, regardless of stage and nodal status. Our community desperately wants more effective tools to help improve their chances against this challenging disease that's turned their life plans upside-down. This Health Canada approval is an exciting step forward." The Health Canada approval is based on the global Phase III NATALEE trial, which included a broad patient population with HR+/HER2- stage II and III eBC. At the final analysis, this clinical trial demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence with ribociclib plus AI compared to AI alone. Among patients with stage II and stage III eBC, ribociclib added to AI demonstrated a 25.1% relative reduction in the risk of an invasive disease-free survival (iDFS) event compared with AI alone,1 with a well-tolerated safety profile seen across all subgroups in pivotal Phase III NATALEE trial.2,4,14,15 "In the NATALEE trial, ribociclib demonstrated significant efficacy for a broad population of patients with early breast cancer,"2 said Dr. Stephen Chia, Medical Oncologist, BC Cancer and Steering Committee member of the NATALEE trial. "This approval provides a new and expanded treatment option for these patients to help reduce their risk of cancer returning. Patients deserve access to the most effective treatment options, and their individual needs should always be at the centre of shared decision making. In every situation, it's critical to have an open, balanced risk-benefit discussion, in order to make the appropriate treatment decision that's best suited for the patient to reduce the risk of their cancer returning." "While the risk of cancer returning peaks in the first five years after diagnosis, more than half of recurrences occur after this period, and the majority are metastatic and incurable,"16,17 said Dr. Katarzyna Jerzak, Medical Oncologist, Sunnybrook Health Sciences Centre. "Ribociclib provides a new treatment option to help reduce the risk of recurrence and improve outcomes, particularly for patients at elevated risk. This approval expands our treatment arsenal with a targeted therapy that will have a meaningful impact on improving the care of patients diagnosed with early breast cancer in Canada." "Novartis has been advancing innovative research and medical practice in breast cancer care for over 35 years, developing one of the most comprehensive pipelines in the field. Over 100,000 people with HR+/HER2- metastatic breast cancer have been treated with KISQALI globally,18 and now we're focused on expanding its use to those with stage II or III HR+/HER2- early breast cancer to reduce risk of recurrence," said Mark Vineis, Country President, Novartis Canada. "We are actively committed to working with our health system partners to ensure timely access to KISQALI and supporting Canadians and healthcare professionals to improve health outcomes." About early breast cancer (eBC)Breast cancer is the most commonly diagnosed cancer among Canadian women, with approximately 70% of cases diagnosed in the early stages of the disease.7,8,11 However, despite existing treatment options, people with stage II and III HR+/HER2- eBC remain at significant risk of recurrence.11,12 The risk of recurrence is influenced by factors such as lymph node involvement, tumor size, age at diagnosis, and biomarkers. While patients without lymph node involvement typically have a lower risk, nearly 25% of those with HR+/HER2- eBC may experience recurrence within 20 years,1 peaking after the first five years.19 However, more than half of recurrences still happen after five years and more than 80% of these cases are metastatic and incurable.20 About KISQALI® (ribociclib tablets)KISQALI was previously approved by Health Canada on March 2, 2018, for the treatment of patients with HR+/HER2- advanced or metastatic breast cancer.20 KISQALI is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.2 In eBC, KISQALI is the only CDK4/6 inhibitor recommended for both all node-positive disease and patients with no nodal involvement with high-risk disease characteristics.20,21 The National Comprehensive Cancer Network (NCCN) guidelines recommend ribociclib (KISQALI) as a Category 1 preferred CDK4/6 inhibitor for breast cancer patients.21 KISQALI, in combination with an AI, has the highest score (A) on the ESMO-Magnitude of Clinical Benefit Scale for the adjuvant treatment of adults with stage II and III HR+/HER2- eBC, at high risk of recurrence.22 The most common Adverse Drug Reactions across the NATALEE study (>20% and exceeding the frequency for AI alone) were neutropenia (62.5% vs. 4.6%), infections (36.3% vs. 26.3%), nausea (23.3% vs.7.8%, headache (23.0% vs. 17.1%), fatigue (22.3% vs. 13.2%), leukopenia (22.3% vs. 3.6%), and abnormal liver function tests (22.3% vs. 7.6%).2 Please see the Product Monograph for KISQALI, available at About NATALEENATALEE is a global Phase III multi-centre, randomized, open-label trial to evaluate the efficacy and safety of KISQALI with an AI as an investigational adjuvant treatment versus AI alone in patients with stage II and III HR+/HER2- eBC. The adjuvant ET in both treatment arms was a non-steroidal aromatase inhibitor (NSAI; anastrozole or letrozole) and goserelin, if applicable. The primary endpoint of NATALEE was invasive disease-free survival (iDFS) as defined by the Standardized Definitions for Efficacy End Points (STEEP) criteria. A total of 5,101 adult patients with HR+/HER2- eBC across 20 countries were randomized in the trial.13,23 About NovartisNovartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit References ________________________________1 Pan H, Gray R, Braybrooke J, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years (incl. supplementary appendix). N Engl J Med. 2017;377(19):1836-1846. doi:10.1056/NEJMoa1701830 2 Novartis. (2025). KISQALI Product Monograph. Accessed June 2025. 3 Hortobagyi G, Stroyakovskiy D. Yardley DA, et al. Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial. Presented at: San Antonio Breast Cancer Symposium 2023 on December 5–9, 2023 San Antonio, TX. 4 Bardia A, Hortobagyi GN, Lipatov O, et al. LBA23: Invasive disease–free survival (iDFS) across key subgroups from the Phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC). Presented at: European Society for Medical Oncology (ESMO) Congress on 23 October 2023. Madrid, Spain. 5 Slamon D, Stroyakovskiy D, Yardley D, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: primary results from the Phase III NATALEE trial. Presented at: the American Society of Clinical Oncology Annual Meeting on June 2, 2023. Chicago, USA. 6 International Agency for Research on Cancer (IARC). Accessed April 2025. 7 American Cancer Society. Breast Cancer Facts & Figures 2019-2020. 2019. Accessed April 2025. 8 Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. doi:10.1093/jnci/dju055 9 Criscitiello C, Spurden D, Piercy J, et al. Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer. Clin Ther. 2021;43(7):1228-1244.e4. doi:10.1016/ 10 Mayo Clinic. Recurrent breast cancer. July 2, 2022. Accessed April 2025. 11 Breast Cancer Now. Breast cancer recurrence. May 2019. Accessed April 2025. 12 FDA Approval. Available from Accessed April 2025 13 Government of Canada. Breast cancer in Canada. Accessed June 2025. 14 Slamon D et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024;390:1080-1091. doi: 10.1056/NEJMoa2305488 15 Yardley D, Untch M, et al. Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC) in NATALEE. Presented at the American Society of Clinical Oncology Annual Meeting; May 31, 2024; Chicago, USA. 16 Geurts YM, Witteveen A, Bretveld R, et al. Patterns and predictors of first and subsequent recurrence in women with early breast cancer. Breast Cancer Res Treat. 2017;165(3):709-720. doi:10.1007/s10549-017-4340-3 17 Wangchinda P, Ithimakin S. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World J Surg Oncol. 2016;14(1):223. Published 2016 Aug 24. doi:10.1186/s12957-016-0988-0 18 Novartis Data on File. 19 Bushnell GG, Deshmukh AP, den Hollander P, et al. Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge. NPJ Breast Cancer. 2021;7(1):66. Published 2021 May 28. doi:10.1038/s41523-021-00269-x 20 Health Canada Approval. Available from Accessed April 2025 21 NCCN Guidelines. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) - Breast Cancer. Accessed May 2025. 22 European Society of Medical Oncology (ESMO). ESMO MCBS scorecards; NATALEE. Available at Accessed April 2025. 23 NCT03701334. A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/ HER2- Early Breast Cancer (NATALEE). Updated October 10, 2024. Available at Accessed April 2025 SOURCE Novartis Pharmaceuticals Canada Inc. View original content to download multimedia: Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store
Colorectal cancer signs, symptoms & screening: Everything you need to know about the 2nd deadliest cancer in Canada